Halozyme announces proposed $1.05B convertible notes due 2033
Halozyme Therapeutics said it intends to offer $1.05 billion of convertible senior notes due 2033, subject to market conditions and other factors.
Site Search
Search market news
Find public news by keyword, exact ticker, category and date.
Matching instruments
Open a ticker page for its news coverage. The news search below stays a text search.